Experimental drug Vytorin (ezetimibe/simvastatin) was found to lower the risk of major vascular events by 16.1% compared to a placebo for patients with chronic kidney disease, Merck & Co announced today. Vytorin is a cholesterol lowering medication. Examples of major vascular events are non-fatal heart attacks, stroke or any type of revascularization procedure. Ezetimibe/simvastatin is currently approved for patients with primary hypercholesterolemia or mixed hyperlipidemia...
More...
More...